催化剂制药 CPRX 深 沪
等待开盘 04-03 09:30:00 美东时间
24.69
-0.130
-0.52%
华盛通- 最 高24.79
- 今 开24.54
- 成交量 61.61万股
- 最 低 24.38
- 昨 收 24.82
- 总市值 30.15亿
- 52周最高 26.58
- 市盈率 静 14.66
- 换手率 0.50%
- 52周最低 19.05
- 委 比 26.01%
- 总股本 1.22亿
- 历史最高 26.58
- 量 比 0.64
- 振 幅 1.65%
- 历史最低 0.37
- 每 手 1
- 风险率 1.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Catalyst Pharmaceuticals Says District Court Delays Bench Trial To May 18, 2026; Bench Trial Concerns Validity Of FIRDAPSE Patents Expiring In 2032, 2034, 2037
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001369568/000119312526114306/d111324d8k.htm
03-19 05:45
Catalyst Pharma To Showcase Real‑World Findings In Duchenne Muscular Dystrophy Through Multiple Poster Presentations At 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and
03-06 21:09
**Catalyst to present DMD real‑world findings at 2026 MDA Clinical & Scientific Conference**
**Catalyst to present DMD real‑world findings at 2026 MDA Clinical & Scientific Conference** Catalyst Pharmaceuticals (CPRX) will present three Duchenne muscular dystrophy real-world posters at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida, on March 8, 2026 (6:00–8:00 PM ET). The
03-06 21:03
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings on vamorolone in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. The company will showcase three poster presentations focusing on vamorolone's safety, healthcare resource utilization, and respiratory outcomes. Additionally, Catalyst will sponsor an MDA Industry Forum with Santhera Pharmaceuticals, featuring insights from clinical lead...
03-06 13:03
财报速睇 | 催化剂制药 2025财年年度营收5.89亿美元，同比增长19.8%；归母净利润2.14亿美元，同比增长30.8%
华盛资讯2月26日讯，催化剂制药公布2025财年年度业绩，公司年度营收5.89亿美元，同比增长19.8%，归母净利润2.14亿美元，同比增长30.8%。
02-26 09:20
财报速睇 | 催化剂制药 2025财年Q4营收1.53亿美元，同比增长7.6%；归母净利润0.53亿美元，同比下滑5.8%
华盛资讯2月26日讯，催化剂制药公布2025财年Q4业绩，公司Q4营收1.53亿美元，同比增长7.6%，归母净利润0.53亿美元，同比下滑5.8%。
02-26 06:05
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Catalyst Pharmaceuticals CEO Rich Daly and management team will participate in the Barclays Global Healthcare Conference on March 10, 2026, in Miami. They will present at 3:30 PM ET, and a webcast will be available on the Company’s website, www.catalystpharma.com, with a replay accessible for 30 days. Catalyst, a biopharmaceutical company focused on rare diseases, has a strong U.S. presence and a track record of successful commercialization. The ...
02-24 13:03
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals will release its 2025 Q4 and full-year financial results on February 25, 2026, after market close. A conference call and webcast to discuss the results and provide a business update will be held on February 26, 2026, at 8:30 AM ET. The event will be accessible via dial-in numbers and live webcast on the company's website, with a replay available for 30 days.
02-11 13:03
Jim Cramer: Crane Is A 'Good' Company, Recommends Holding This Tech Stock
Jim Cramer recommended holding Texas Instruments (TXN) on CNBC's Mad Money, supported by an analyst's hold rating and raised price target. He also praised Crane Company (CR) and Catalyst Pharmaceuticals (CPRX) for their strong earnings.
01-15 01:26
